Analyst Ratings For KemPharm (NASDAQ:KMPH) (NASDAQ:KMPH)
Today, Oppenheimer reiterated its Buy rating on KemPharm (NASDAQ:KMPH) (NASDAQ:KMPH).
Some recent analyst ratings include
- 3/22/2018-Oppenheimer Reiterated Rating of Buy.
- 6/28/2017-Roth Capital initiated coverage with a Buy rating.
Recent Insider Trading Activity For KemPharm (NASDAQ:KMPH) (NASDAQ:KMPH)
KemPharm (NASDAQ:KMPH) (NASDAQ:KMPH) has insider ownership of 25.40% and institutional ownership of 36.56%.
- On 11/27/2017 Daniel L Cohen, EVP, bought 7,500 with an average share price of $3.79 per share and the total transaction amounting to $28,425.00.
- On 9/25/2017 R. Laduane Clifton, CFO, bought 300 with an average share price of $3.78 per share and the total transaction amounting to $1,134.00.
- On 9/14/2017 Delaware Street Capital Master, Major Shareholder, bought 325,888 with an average share price of $3.27 per share and the total transaction amounting to $1,065,653.76.
- On 8/24/2017 Daniel L Cohen, EVP, bought 5,000 with an average share price of $2.58 per share and the total transaction amounting to $12,900.00.
- On 8/24/2017 Gordon K Johnson, Insider, bought 4,000 with an average share price of $2.60 per share and the total transaction amounting to $10,400.00.
- On 6/20/2017 Travis C Mickle, CEO, bought 8,000 with an average share price of $3.45 per share and the total transaction amounting to $27,600.00.
- On 6/19/2017 R. Laduane Clifton, CFO, bought 275 with an average share price of $3.30 per share and the total transaction amounting to $907.50.
Recent Trading Activity for KemPharm (NASDAQ:KMPH) (NASDAQ:KMPH)
Shares of KemPharm (NASDAQ:KMPH) closed the previous trading session at 7.35 down -0.65 8.13% with 8.0 shares trading hands.